Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: acid therapy + hepatitis + 0.31  Related to the article below (Last Update: 8/5/2008)

Lymphocytic Choriomeningitis Virus Transmitted Through Solid Organ ...
RedOrbit, TX - 27 minutes ago
Of 11 recipients described in those clusters, 10 died of multisystem organ failure, with LCMVassociated hepatitis as a prominent feature. ...
EU Panel Backs GSK's Pre-Pandemic Influenza Vaccine
CNNMoney.com - Jul 25, 2008
Ribavirin "iQur" (ribavirin), from iQur Pharmaceutical Ltd, is indicated for the treatment of chronic hepatitis C and to be used only in combination with ...
Roche posts very good results: strong market outperformance ...
Business-News, Switzerland - Jul 20, 2008
Virology ? latest Pegasys approval enables personalised hepatitis C therapy Pegasys (peginterferon alfa-2a), for the treatment of hepatitis B and C, ...

Age of Autism
Heckenlively on the Omnibus Autism Proceeding 7/21-23
Age of Autism, Trumbull - Jul 30, 2008
Colin received 4 hepatitis B vaccines rather than the usual 3 vaccines. Although Colin started the gluten/casein free diet, the Dwyers noticed later that it ...
Giaconda Suspends Hepaconda Phase II Trial
FDA news (subscription), VA - Jul 15, 2008
... suspended its Phase IIa trial of Hepaconda for the treatment of hepatitis C in people with Type 1 infection that does not respond to current therapy. ...
Workplace-Based Investigation of Contacts of a Patient With Highly ...
Journal of American Medical Association (subscription), IL - Jul 15, 2008
Because TB was suspected, he was admitted to an airborne-infection isolation room and administered anti-TB therapy. Chest radiography and computed ...
A 50-Year-Old Woman Addicted to Heroin
Journal of American Medical Association (subscription), IL - Jul 15, 2008
Her medical history is notable for hypertension and hepatitis C virus, which has been successfully treated so that her viral load is undetectable. ...
Source: Google News

… of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid -
V Leroy, F Monier, S Bottari, C Trocme, N Sturm, … - American Journal of Gastroenterology, 2004 - Blackwell Synergy
... Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis
type C ... Measurement of serum hyaluronic acid in patients with chronic ...

… Predict Response to Interferon Therapy in Japanese Patients with Chronic Hepatitis C and Cirrhosis -
S Murashima, T Ide, I Miyajima, R Kumashiro, T … - Scandinavian Journal of Infectious Diseases, 1999 - ingentaconnect.com
... Mutations of hepatitis C virus 1b NS5A 2209? 2248 amino acid sequence do not predict
the response to recombinant interferon-alfa therapy in French ...

Racial differences in responses to therapy with interferon in chronic hepatitis C -
KR Reddy, JH Hoofnagle, MJ Tong, WM Lee, P Pockros, … - Hepatology, 1999 - doi.wiley.com
... to interferon; a 40? amino acid stretch in ... evaluate response rates to interferon
therapy by racial ... of 40 African-American patients with chronic hepatitis C re ...

… -Alpha plus Ursodeoxycholic Acid versus Interferon plus Placebo in Patients with Chronic Hepatitis C … -
RE Poupon - Scandinavian Journal of Gastroenterology, 2000 - informaworld.com
... Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic
viral C hepatitis: results from a controlled randomized trial in ...

Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti- … -
D Nelson? - Hepatology, 2003 - doi.wiley.com
... in the treat- ment of chronic hepatitis C and ... a free amine N-termini and free acid
C-termini. ... infection or clear chronic in- fection after interferon therapy. ...

… by failure to racemize trihydroxycholestanoic acid: Gene mutation and effect of bile acid therapy -
KDR Setchell, JE Heubi, KE Bove, NC O'Connell, T … - Gastroenterology, 2003 - Elsevier
... Results: Liver biopsy specimens showed neonatal hepatitis with giant cell
transformation and ... Primary bile acid therapy with cholic acid has proved effective ...

Bile acids for viral hepatitis. -
W Chen, J Liu, C Gluud - ncbi.nlm.nih.gov
... In one trial, ursodeoxycholic acid (UDCA) versus placebo for ... or without co-interventions
for chronic hepatitis C. Bile ... WMD 0.20, 95% CI 0.08 to 0.31) at the ...

Resistance Surveillance in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil for Up to 60 … -
H Yang, CE Westland, WE Delaney IV, EJ Heathcote, … - therapy, 2002 - doi.wiley.com
... hepadnaviruses, includ- ing HBV, woodchuck hepatitis virus, and ... and 48 weeks of
open-label therapy. Several previously unreported amino acid substitutions were ...

… therapy with thymosin 1 and interferon for the treatment of chronic hepatitis C infection: a … -
KE Sherman, M Sjogren, R Creager, MA Damiano, S … - Hepatology, 1998 - doi.wiley.com
... The 28?amino acid peptide is one member of ... One patient required thyroid replacement
therapy for hypo- thyroidism ... the mainstay of treatment of hepatitis C. In ...

… and virological factors associated with response to alpha interferon therapy in chronic hepatitis C -
JA Garson, S Brillanti, K Whitby, M Foli, R … - J Med Virol, 1995 - doi.wiley.com
... ity of those treated gain no long-term benefit from the therapy. ... Interferon Response
Factors in Hepatitis C 351 ... Log,, HCV genomedml 5.6 2 0.24 5.7 f 0.31 4.5 2 ...

Source: Google Scholar

Bile acid may improve hepatitis C therapy response

Last Updated: 2007-12-11 13:05:32 -0400 (Reuters Health)

By David Douglas

NEW YORK (Reuters Health) - A bile acid - called ursodeoxycholic acid -- may improve response to treatment in patients with chronic hepatitis C virus (HCV) who don't respond to standard therapy with interferon and ribavirin, Japanese researchers report in the medical journal Gut.

Ursodeoxycholic acid is a secondary bile acid that breaks down fat, and reduces the amount of cholesterol produced by the liver and absorbed by the intestines. It also helps break down cholesterol that has formed into gall stones and increases bile flow in patients with primary biliary cirrhosis.

Ursodeoxycholic acid therapy, which reduces levels of a type of enzyme (aminotransferase), may slow the progression of liver fibrosis and prevent the development of liver cancer, Dr. Masao Omata told Reuters Health.

Omata, of the University of Tokyo Graduate School of Medicine, and colleagues note that 1b is the most common HCV strain in Japan and can be resistance even to combination therapy. Only about 50 percent of patients with this HCV type have a sustained response to treatment.

To investigate whether the addition of ursodeoxycholic acid can improve treatment results, the researchers studied 596 patients who had elevated levels of the liver enzyme alanine aminotransferase (ALT). The patients were randomly assigned to receive one of three daily doses of ursodeoxycholic acid for 24 weeks.

ALT, as well as two additional liver enzymes, aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT), decreased at week 4 and then remained constant during drug administration.

Changes in ALT and AST did not differ in the patients who received the two higher doses -- 600 milligrams (mg) or 900 mg -- but GCT was significantly lower in the 900 mg group. In patients with initial GCT levels exceeding 80 IU/L who received 900 mg, ALT also showed a significant decrease.

However, there was no change in blood levels of HCV in any of the groups. Overall, 19.1 percent of patients reported adverse effects, but there were no differences in adverse effects among three groups.

Based on the findings, "there is not sufficient data to advise ursodeoxycholic acid treatment in hepatitis C," co-author of an accompanying editorial Dr. Raoul Poupon of Universite Pierre and Marie Curie, Paris told Reuters Health.

SOURCE: Gut, December 2007.

.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.